CRANDELL KEITH 4
4 · Boundless Bio, Inc. · Filed Jul 6, 2026
Research Summary
AI-generated summary of this filing
Boundless Bio (BOLD) 10% Owner Keith Crandell Exercises Options, Sells Shares
What Happened
Keith Crandell (reported as a 10% owner through ARCH-related entities) exercised/converted derivatives and sold shares on July 1, 2026. The filing shows an exercise/acquisition of 16,000 shares at $1.03 per share (cost $16,480) and an open‑market sale of 16,000 shares at $2.49 per share (proceeds $39,840). The report also lists a separate derivative conversion of 16,000 shares reported with $0.00 consideration. Overall, the net public sale reported was 16,000 shares for $39,840 (a disposition).
Key Details
- Transaction date: July 1, 2026 (filed on Form 4 dated July 6, 2026).
- Prices and amounts: exercised 16,000 @ $1.03 (acquired; $16,480); sold 16,000 @ $2.49 (disposed; $39,840); one derivative conversion of 16,000 @ $0.00 (disposed).
- Shares owned after transaction: not specified in the provided excerpt.
- Footnotes: transactions are reported in connection with ARCH venture funds and related entities (see F2–F6) — beneficial ownership is reported through those funds, and various ARCH entities disclaim direct beneficial ownership except to extent of any pecuniary interest. The filing is one of two reports filed jointly by multiple ARCH parties and individuals.
- Timeliness: Transaction reported on July 6 for a July 1 trade — appears to have been filed after the typical two-business‑day Form 4 deadline.
Context
These filings reflect activity by a 10% owner via venture/investment entities (ARCH/AVP structures), not necessarily personal trading by an executive. The "M" transaction codes indicate exercises/conversions of derivatives (e.g., options); here shares acquired by exercise were sold in the open market on the same date. Retail investors often view immediate sell‑offs after option exercises as routine liquidity or fund rebalancing by institutional holders rather than a direct signal about company prospects.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-07-01$1.03/sh+16,000$16,480→ 16,000 total(indirect: See footnote) - Sale
Common Stock
[F1]2026-07-01$2.49/sh−16,000$39,840→ 0 total(indirect: See footnote) - Exercise/Conversion
Stock Option (right to buy)
[F7][F1]2026-07-01−16,000→ 0 total(indirect: See footnote)Exercise: $1.03Exp: 2035-06-22→ Common Stock (16,000 underlying)
- 683,759(indirect: See footnotes)
Common Stock
[F2][F4] - 828,570(indirect: See footnotes)
Common Stock
[F3][F4] - 1,181,766(indirect: See footnotes)
Common Stock
[F5][F6]
Footnotes (7)
- [F1]Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer.
- [F2]Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
- [F3]Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
- [F4]ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any.
- [F5]Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
- [F6]ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Kristina Burow, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
- [F7]The stock option vested in substantially equal monthly installments over the 11 months following June 23, 2025. The final unvested portion vested on June 15, 2026, the date of the Issuer's 2026 annual meeting of stockholders.